Claire L Meek1,2, Hannah B Lewis1,2, Keith Burling2,3, Frank Reimann1,2, Fiona Gribble1,2. 1. Wellcome Trust-MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. 2. Department of Clinical Biochemistry, Cambridge University Hospitals, Addenbrooke's Hospital, Cambridge, UK. 3. Core Biochemical Assay Laboratory, Addenbrooke's Hospital, Hills Road, Cambridge, UK.
Abstract
BACKGROUND: Gastrointestinal hormones regulate intestinal transit, control digestion, influence appetite and promote satiety. Altered production or action of gut hormones, including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY), may contribute to the biological basis of obesity and altered glucose homeostasis. However, challenges in analytical methodology and lack of clarity on expected values for healthy individuals have limited progress in this field. The aim of this study was to describe expected concentrations of gastrointestinal and pancreatic hormones in healthy volunteers following a standardized meal test (SMT) or 75 g oral glucose tolerance test (OGTT). METHODS: A total of 28 healthy volunteers (12 men, 16 women; mean age 31.3 years; mean body mass index 24.9 kg/m2) were recruited to attend a hospital clinic on two occasions. Volunteers had blood sampling in the fasting state and were given, in randomized order, an oral glucose tolerance test (OGTT) and standardized mixed liquid meal test with venepuncture at timed intervals for 4 h after ingestion. Analytical methods for gut and pancreatic hormones were assessed and optimized. Concentrations of gut and pancreatic hormones were measured and used to compile ranges of expected values. RESULTS: Ranges of expected values were created for glucose, insulin, glucagon, GLP-1, GIP, PYY and free fatty acids in response to a standardized mixed liquid meal or OGTT. Intact proinsulin and C-peptide levels were also measured following the OGTT. CONCLUSIONS: These ranges of expected values can now be used to compare gut hormone concentrations between healthy individuals and patient groups.
BACKGROUND: Gastrointestinal hormones regulate intestinal transit, control digestion, influence appetite and promote satiety. Altered production or action of gut hormones, including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY), may contribute to the biological basis of obesity and altered glucose homeostasis. However, challenges in analytical methodology and lack of clarity on expected values for healthy individuals have limited progress in this field. The aim of this study was to describe expected concentrations of gastrointestinal and pancreatic hormones in healthy volunteers following a standardized meal test (SMT) or 75 g oral glucose tolerance test (OGTT). METHODS: A total of 28 healthy volunteers (12 men, 16 women; mean age 31.3 years; mean body mass index 24.9 kg/m2) were recruited to attend a hospital clinic on two occasions. Volunteers had blood sampling in the fasting state and were given, in randomized order, an oral glucose tolerance test (OGTT) and standardized mixed liquid meal test with venepuncture at timed intervals for 4 h after ingestion. Analytical methods for gut and pancreatic hormones were assessed and optimized. Concentrations of gut and pancreatic hormones were measured and used to compile ranges of expected values. RESULTS: Ranges of expected values were created for glucose, insulin, glucagon, GLP-1, GIP, PYY and free fatty acids in response to a standardized mixed liquid meal or OGTT. Intact proinsulin and C-peptide levels were also measured following the OGTT. CONCLUSIONS: These ranges of expected values can now be used to compare gut hormone concentrations between healthy individuals and patient groups.
Authors: M J Bak; N J Wewer Albrechtsen; J Pedersen; F K Knop; T Vilsbøll; N B Jørgensen; B Hartmann; C F Deacon; L O Dragsted; J J Holst Journal: Diabetes Obes Metab Date: 2014-07-22 Impact factor: 6.577
Authors: Shareen Forbes; May Moonan; Stephen Robinson; Victor Anyaoku; Michael Patterson; Kevin G Murphy; Mohammed A Ghatei; Stephen R Bloom; Desmond G Johnston Journal: Clin Endocrinol (Oxf) Date: 2005-01 Impact factor: 3.478
Authors: S H Jacobsen; S C Olesen; C Dirksen; N B Jørgensen; K N Bojsen-Møller; U Kielgast; D Worm; T Almdal; L S Naver; L E Hvolris; J F Rehfeld; B S Wulff; T R Clausen; D L Hansen; J J Holst; S Madsbad Journal: Obes Surg Date: 2012-07 Impact factor: 4.129
Authors: Rachel L Batterham; Helen Heffron; Saloni Kapoor; Joanna E Chivers; Keval Chandarana; Herbert Herzog; Carel W Le Roux; E Louise Thomas; Jimmy D Bell; Dominic J Withers Journal: Cell Metab Date: 2006-09 Impact factor: 27.287
Authors: Hannah B Lewis; Amy L Ahern; Ivonne Solis-Trapala; Celia G Walker; Frank Reimann; Fiona M Gribble; Susan A Jebb Journal: Obesity (Silver Spring) Date: 2015-06-05 Impact factor: 5.002